Severe insulin resistance type A is due to mutations in the insulin receptor gene and is characterized by glucose intolerance or diabetes mellitus, despite extreme hyperinsulinemia, virilization and acanthosis nigricans. At present, there is no therapy for this condition. Recently, we showed that glucose levels in three such patients are promptly lowered by an iv bolus of recombinant human insulin-like growth factor I (rhIGF-I). In the present study, we investigated two of these rare patients again and determined fasting and postprandial glucose, insulin, C-peptide, proinsulin and lipid levels during five control, five treatment and three wash-out days while on a constant diet. Treatment consisted of 2 \m=x\ 150 \ g=m\ g rhIGF-I/kg sc per day, which elevated total IGF-I levels 4.5-fold above the control. Fasting glucose levels (days 1\p=n-\5) in the two patients were 9.6\m=+-\1.3 and 9.2 \m=+-\1.2 mmol/l, respectively, and fell to 4.4\m=+-\0.4and 5.1\m=+-\0.5mmol/l on treatment days 8\p=n-\10. Fasting insulin (2950\m=+-\450 and 690\m=+-\125 pmol/l), C-peptide (2217\m=+-\183 and 1317\m=+-\235pmol/l) and proinsulin control levels (125\m=+-\35 and 66\m=+-\0pmol/l) also decreased by \m=~\65% during rhIGH-I treatment, as did the respective postprandial levels. Lipid levels hardly changed at all. In conclusion, IGF-I appears to correct partially some metabolic sequelae of severe insulin resistance and may, hence, be used as a new therapeutic agent.
by Kahn et (3) . An iv bolus of recombinant human (rh)IGF-I in healthy subjects leads to a marked transitory increase of free IGF-I levels followed by hypoglycemia (4, 5) . The hypoglycémie effects of IGF-I are mediated via the insulin and the type 1 IGF receptor.
Maximal effects of IGF-I on glucose uptake are similar or even greater than those of insulin in healthy and moderately insulin-resistant diabetic animals (6, 7) .
Thus, the effect of an iv bolus of rhIGF-I was investigated in patients with severe insulin resistance type A (8) and in a patient with Mendenhall's syndrome, also characterized by severel insulin resis¬ tance (9) . Intravenous rhIGF-I lowered plasma glucose and decreased insulin levels in these patients but the fall of glucose was slow (8, 9) 13) . Fasting GH levels in MR and AS were 2.0 ± 1.2 and 3.3 ± 3.3 (control), 0, 7 ± 0.3 and 1.5 ± 0.9 (treatment) and 1.7 ± 0.8 and 3.3 ± 0.9/xg/l (wash-out), respectively.
Fasting plasma glucose levels ( Fig. 2) fell into the normal range on day 9 or 10 and increased during the wash-out period in MR but not in AS. In MR and AS, plasma glucose levels before lunch were 15.5 ± 1.8 and 13.1 ± 1.1 (control), 10.2 ± 0.9 and 6.3 ± 1.3 (treat¬ ment) and 13.1 ±0.7 and 7.4 ± 2.4mmol/l (wash¬ out), respectively. The respective values before dinner were 12.3 ± 2.3 and 11.6 ±0.7 (control), 9.3 ±2.0 and 7.0 ±1.3 (treatment) and 8.0 and 9.3 mmol/1 (wash-out). Postprandial plasma glucose levels changed similarly (Fig. 3) . Fructosamine levels decreased between days 6 and 10 from 430 to 377 (MR) and from 431 to 380/xmol/l (AS).
Fasting insulin levels were 20-(MR) and 4-fold (AS) elevated during the control period compared to healthy controls and decreased by 65% in both patients during treatment, as did C-peptide levels (Fig. 2) . The fasting Cpeptide/insulin ratios were 0.87 ±0.23 (MR) and 1.90 ±0.22 (AS) during the control period and 1.03 ± 0.08 (MR) and 1.76 ± 0.34 (AS) on treatment days [8] [9] [10] . Postprandial insulin secretion (Fig. 3 ) also was reduced during treatment but peak levels (at 10 .00 h) were not delayed compared to the control period. During the wash-out period, fasting and postprandial insulin and C-peptide levels rose more rapidly than glucose levels. The mean proinsulin levels of the two patients in the fasting state and 2 h following breakfast were 96 and 156 (days 4-5), 38 and 80 (days 8-9) and 69 and 174pmoI/l (day 12), respectively.
Fasting lipid levels are shown in Table 2 . Postprandial AUCs for total triglycérides in MR and AS were 3.7 and 6.4 (control), 4 (10) . This prolongs the half-time of insulin, as supported by the very low C-peptide/insulin ratio in the insulin-resistant patients. This mechanism also could explain the much slower decline of insulin levels following an iv bolus of rhIGF-I in severe insulin-resistant patients (8, 9) than in healthy subjects (4, 19 
